PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting

Simple item page
dc.contributor.authorRojo Arnao, María
dc.contributor.authorMartínez De La Casa Fernández-Borrella, José María
dc.contributor.authorAlbis Donado, Óscar
dc.contributor.authorYáñez Castro, Giovanni
dc.contributor.authorMaroto Cejudo, Raquel
dc.contributor.authorTéllez, Jesús
dc.contributor.authorMenoyo Calatayud, Ricardo
dc.date.accessioned2024-01-15T20:02:17Z
dc.date.available2024-01-15T20:02:17Z
dc.date.issued2023-12-26
dc.description.abstractPurpose: This study aims to assess the effectiveness and safety of combining the Preserflo™ MicroShunt implant (MicroShunt) with a simultaneous Ologen™ implant in patients with glaucoma. Methods: We conducted a retrospective study on consecutive patients with medically uncontrolled glaucoma who underwent MicroShunt + Ologen implantation as a standalone procedure or in combination with phacoemulsification (combined procedure). Success was defined as achieving an intraocular pressure (IOP) of 6-15 mmHg at 18 months post surgery, with a preoperative IOP reduction of at least 20%, and without (complete success) or with (qualified success) the need for antiglaucoma medications. The primary endpoint was the success rate. Results: Forty-eight eyes from 47 patients were included, with 28 eyes (58.3%) undergoing the standalone procedure and 20 eyes (41.7%) undergoing the combined procedure. Overall, there was a significant reduction in preoperative IOP from 19.7 ± 5.8 mmHg to 11.4 ± 2.6 mmHg at 18 months (P < 0.0001). In the standalone procedure group, preoperative IOP decreased from 21.5 ± 5.2 mmHg to 11.7 ± 2.5 mmHg (P < 0.0001), and in the combined procedure group, preoperative IOP decreased from 17.1 ± 5.8 mmHg to 10.9 ± 2.7 mmHg (P = 0.0002), with no significant difference between the two groups regarding final IOP. The mean number of antiglaucoma medications significantly decreased from 3.2 ± 1.1 to 0.3 ± 0.7 in the overall study population (P < 0.0001). At 18 months, 40 eyes (83.3%) were classified as successful. Regarding safety, out of the total number of eyes, two (4.2%) experienced choroidal detachment without visual impairment, two (4.2%) had transient hyphema, one (2.1%) showed reactivation of a corneal herpetic ulcer, one (2.1%) had diplopia, and one (2.1%) exhibited a shallow anterior chamber during the first week. Conclusion: The combination of Ologen™ and Preserflo™ MicroShunt, either alone or in conjunction with phacoemulsification, demonstrated a favorable profile in terms of IOP reduction and safety.en
dc.description.departmentDepto. de Inmunología, Oftalmología y ORL
dc.description.facultyFac. de Medicina
dc.description.facultyFac. de Óptica y Optometría
dc.description.refereedTRUE
dc.description.statusinpress
dc.identifier.citation: Rojo‑Arnao M, Martinez‑de‑la‑Casa JM, Albis‑Donado O, Yañez‑Castro G, Maroto‑Cejudo R, Téllez J, et al. PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting. Indian J Ophthalmol 0;0:0.
dc.identifier.doi10.4103/IJO.IJO_1502_23
dc.identifier.essn1998-3689
dc.identifier.issn0301-4738
dc.identifier.officialurlhttps://journals.lww.com/ijo/abstract/9900/preserflotm_microshunt_implantation_combined_with.51.aspx
dc.identifier.pmid38153975
dc.identifier.urihttps://hdl.handle.net/20.500.14352/93229
dc.journal.titleIndian Journal of Ophthalmology
dc.language.isoeng
dc.publisherWolters Kluwer
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subject.cdu617.7-007.681
dc.subject.cdu617.7-089
dc.subject.keywordGlaucoma
dc.subject.keywordGlaucoma surgery
dc.subject.keywordIntraocular pressure
dc.subject.keywordMIGS, Ologen
dc.subject.keywordPreserflo MicroShunt
dc.subject.ucmOftalmología
dc.subject.ucmCirugía
dc.subject.unesco3201.09 Oftalmología
dc.subject.unesco3213.09 Cirugía Ocular
dc.titlePreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical settingen
dc.typejournal article
dc.type.hasVersionAM
dspace.entity.typePublication
relation.isAuthorOfPublication273a99c3-2c9f-4dd0-8939-b7ff3593124c
relation.isAuthorOfPublication.latestForDiscovery273a99c3-2c9f-4dd0-8939-b7ff3593124c
Download
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
preserflotm_microshunt_implantation_combined_with.51.pdf
Size:
1.86 MB
Format:
Adobe Portable Document Format
downoload Download
Collections
Artículos